B+
Bull case
30%
Probability
Target price
$228.00
+37.6% vs current
ENSG
Ensign GroupDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$212.00
+27.9% vs current
B-
Bear case
25%
Probability
Target price
$176.00
+6.2% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+74.7
Score
AI commentary
Sentiment is cautiously constructive, not euphoric. Primary sources support a positive operating backdrop: 2025 adjusted EPS rose to $6.57, same-facility occupancy hit record levels, 2026 guidance implies another step-up, and February acquisitions expanded the footprint further [#8-K-2026-02-04][#PR-2026-02-04][#PR-2026-02-03-TX]. Peer context is now grounded in post-acute operators rather than generic medtech comps, but the thesis remains a monitoring-style buy because reimbursement and integration risks are material and near-term external confirmation beyond company filings and releases is still limited [#10-K-2026-02-04][#IR-PACS][#IR-EHC].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-04-30catalystDividend payment and near-term cash-return checkpointMedium impact
Ensign declared a quarterly dividend of $0.065 per share payable on or before April 30, 2026. The dividend itself is not a major valuation driver, but it reinforces balance-sheet capacity and management's confidence while investors wait for the next operating update [#PR-2026-03-20].
2026-06-30eventFebruary 2026 acquisitions begin contributing to run-rate revenue and real-estate earningsHigh impact
On February 1, 2026 Ensign added multiple facilities in Arizona, Texas and Wisconsin, taking the portfolio to 378 healthcare operations and 160 real estate assets. If the company integrates these assets with its usual cluster playbook, Q2/Q3 2026 comparisons should benefit from added beds, lease income and acquired operations layering into the base [#PR-2026-02-03-AZ][#PR-2026-02-03-TX][#10-K-2026-02-04].
2026-12-31catalyst2026 guidance execution against still-rising occupancy and skilled mixHigh impact
The core bull case remains that Ensign can convert record 2025 occupancy, skilled-day growth and Medicare mix into another year of double-digit EPS growth. Management guided 2026 diluted EPS to $7.41-$7.61 and revenue to $5.77B-$5.84B, with guidance assuming acquisitions expected to close through Q1 2026 and current reimbursement expectations [#8-K-2026-02-04][#PR-2026-02-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology